Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Through an analysis of Eli Lilly, we can infer the following trends: At 86.87, the stock's Price to Earnings ratio significantly exceeds the industry average by 3.52x, suggesting a premium ...

In this note, we discuss Eli Lilly’s stock performance, key takeaways from its recent results, and valuation. Firstly, let us look at its stock performance.

Eli Lilly shares tumble 12.5% in November, on track for their worst monthly performance since February 2009’s 20.2% drop. Past sell-offs signal resilience: LLY averaged double-digit rebounds one ...

Eli Lilly's Q1 numbers showed strong revenue and earnings growth, driven by its GLP-1 offerings. The company's 2025 outlook disappointed investors, however, leading to the decline. The stock ...

Eli Lilly has been a huge winner with its GLP-1 drugs. Powered by its popular GLP-1 weight loss drugs, Eli Lilly 's stock (LLY -1.06%) has had a strong run this year, up more than 55%.

The stock's fall snapped a four-day winning streak.

Eli Lilly Earnings: Solid Performance Overshadowed by Novo’s Obesity Coverage Win We continue to view Lilly stock as overvalued.